project . 2020 - 2025 . On going

Trep-AB

Repurposing clinically approved antibacterial drugs for treponematoses therapy
Open Access mandate for Publications European Commission
  • Funder: European CommissionProject code: 850450 Call for proposal: ERC-2019-STG
  • Funded under: H2020 | ERC | ERC-STG Overall Budget: 1,498,790 EURFunder Contribution: 1,498,790 EUR
  • Status: On going
  • Start Date
    01 Feb 2020
    End Date
    31 Jan 2025
  • Detailed project information (CORDIS)
  • Open Access mandate
    Research Data: No
Description
Current therapeutic options for human treponematoses, syphilis and yaws, are, broadly speaking, restricted to one antibiotic: injectable penicillin. The drug susceptibility profile of Treponema pallidum (T.p) is unknown because the microorganism could not be grown in culture. Treatment failure after penicillin has been related to syphilis bacteria that survive in the central nervous system (CNS) and the potential of strains to acquire resistance to penicillin has recently been recognized. Yaws can be treated with azithromycin but there is a real risk that macrolide-resistant strains disseminate widely and jeopardize the global eradication campaign. I propose a r...
Partners
Description
Current therapeutic options for human treponematoses, syphilis and yaws, are, broadly speaking, restricted to one antibiotic: injectable penicillin. The drug susceptibility profile of Treponema pallidum (T.p) is unknown because the microorganism could not be grown in culture. Treatment failure after penicillin has been related to syphilis bacteria that survive in the central nervous system (CNS) and the potential of strains to acquire resistance to penicillin has recently been recognized. Yaws can be treated with azithromycin but there is a real risk that macrolide-resistant strains disseminate widely and jeopardize the global eradication campaign. I propose a r...
Partners
Any information missing or wrong?Report an Issue